Companies are striving to keep staff safe while maintaining the supply of systems for vaccine development. Crisis on supply chains, production, and shipments to customers has still been manageable, but the high dynamics of this situation are challenging.
The goal is to meet the increasing demand for new biologics, cell and gene therapies, and drug products.
From a manufacturing perspective theranostics, including bespoke cell and gene therapies, are a paradigm change for which established production strategies will not work.
AI is having a weighty effect on efficiency and reproducibility, which will profoundly affect the management of personnel.
A triple helix structure and other biological properties are featured that mimic attributes of natural collagen so it can interact with cells and tissues.
The collaborations include tech transferring cell therapy manufacturing processes developed independently at the Stanford University School of Medicine, Fred Hutchinson Cancer Research Center, and Parker Institute for Cancer Immunotherapy into the platform.
Please wait while you are redirected to the right page...